Table 4.
Safety outcomes of the included studies.
| Reference | G3–5 AEs | Pneumonitis (≥G3) | Drug-related death | |||
|---|---|---|---|---|---|---|
| Pembro/Pembro+Chemo | Chemo | Pembro/Pembro+Chemo | Chemo | Pembro/Pembro+Chemo | Chemo | |
| RCT studies | ||||||
| D. Rodríguez (24) | 212/405 (52.4%) | 84/202 (41.6%) | NR | NR | 8/405 (2.0%) | 2/202 (1.0%) |
| Luis Paz-Ares (26) | 206/278 (74.1%) | 195/280 (69.6%) | 9/278 (3.2%) | 3/280 (1.1%) | 12/278 (4.3%) | 5/280 (1.8%) |
| Mark M. Awad (27) | 23/59 (40.0%) | 19/62 (30.7%) | 4/59 (6.8%) | 0/62 (0%) | 1/59 (1.7%) | 2/62 (3.2%) |
| Oscar Arrieta (28) | NR | NR | 0/40 (0%) | 0/38 (0%) | NR | NR |
| Cheng Y (29) | 53/65 (81.5%) | 49/60 (81.7%) | 0/65 (0%) | 0/60 (0%) | 1/65 (1.5%) | 1/60 (1.7%) |
| Hidehito Horinouchi (30) | 18/25 (72.0%) | 9/15 (60.0%) | 1/25 (4.0%) | 2/15 (13.3%) | 0/25 (0%) | 0/15 (0%) |
| Martin Reck (31) | 48/154 (31.2%) | 80/150 (53.3%) | 5/154 (3.3%) | 1/150 (0.7%) | 2/154 (1.3%) | 3/150 (2.0%) |
| R S Herbst (33) | 110/682 (16.1%) | 113/309 (36.6%) | 18/682 (2.6%) | 2/309 (0.6%) | 5/682 (0.7%) | 5/309 (1.6%) |
| Tony S K Mok (14) | 113/636 (17.8%) | 252/615 (41.0%) | 22/636 (3.5%) | 1/615 (0.2%) | 13/636 (2.0%) | 14/615 (2.3%) |
| Wu YL (38) | 25/128 (19.5%) | 86/125 (68.8%) | 3/128 (2.3%) | 0/125 (0%) | 7/128 (5.5%) | 4/125 (3.2%) |
| Retrospective studies | ||||||
| Liao JT (40) | 25/49 (51.0%) | 17/53 (32.1%) | 1/49 (2.0%) | 0/53 (0%) | 1/49 (2.0%) | 0/53 (0%) |
| Zhang J (41) | 17/34 (50.0%) | 12/32 (37.5%) | NR | NR | 0/34 (0%) | 0/32 (0%) |
| Alessio Cortellini (42) | NR | — | 23/1010 (2.3%) | — | NR | — |
| Doran Ksienski (45) | NR | — | 1/190 (0.5%) | — | NR | — |
| Hisao Imai (49) | NR | — | 1/46 (2.1%) | — | 2/47 (4.3%) | — |
| Motohiro Tamiya (53) | 39/213 (18.3%) | — | 10/213 (4.7%) | — | NR | — |
| Yuichi Tambo (56) | 18/95 (19.0%) | — | 13/95 (13.7%) | — | NR | — |
| Nikolaj Frost (18) | 24/153 (15.7%) | — | 5/153 (3.3%) | — | NR | — |
Pembro, Pembrolizumab; Chemo, Chemotherapy; NR, Not Reported.